Effects of Cholinergic Lesions and Cholinesterase Inhibitors on Aromatase and Estrogen Receptor Expression in Different Regions of the Rat Brain. (1st August 2018)

• Record Type: Journal Article
• Authors: Li, Junyi; Rao, Di; Gibbs, Robert B.
• Is Part Of: Neuroscience. Volume 384(2018)
• Page Start: 203
• Page End: 213
• Publication Date: 2018-08-01
• Subjects: ACh acetylcholine -- ARO aromatase -- CamKII calcium/calmodulin-dependent protein kinases -- ChAT choline acetyltransferase -- ChEIs cholinesterase inhibitors -- CREB cAMP response element-binding proteins -- DMP delayed-matching-to-position -- ERs estrogen receptors -- IHC immunohistochemistry -- IR immunoreactivity -- MAPK mitogen-activated protein kinases -- MS medial septum -- NBM nucleus basalis magnocellularis -- POA preoptic area; local estrogen production -- 192IgG-saporin -- donepezil -- galantamine -- amygdala; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2018.05.033
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: This paper applied a novel UPLC–MS/MS method to detect aromatase (ARO) activity in the brain tissue. Medial septum selective cholinergic lesion did not regulate ARO and estrogen receptors (ERs) in the hippocampus. Cholinesterase inhibitors injection has no influence on ARO and ERs in several brain regions. Galantamine increased ARO activity with no change of ARO mRNA in the amygdala. Abstract: Cholinergic projections have been shown to interact with estrogens in ways that influence synaptic plasticity and cognitive performance. The mechanisms are not well understood. The goal of this study was to investigate whether cholinergic projections influence brain estrogen production by affecting aromatase (ARO), or influence estrogen signaling by affecting estrogen receptor expression. In the first experiment, ovariectomized rats received intraseptal injection of the selective immunotoxin 192IgG-saporin to destroy cholinergic inputs to the hippocampus. In the second experiment ovariectomized rats received daily intraperitoneal injections of the cholinesterase inhibitors donepezil or galantamine for 1 week. ARO activity and relative levels of ARO, ERα, ERß, and GPR30 mRNAs were quantified in the hippocampus, frontal cortex, amygdala and preoptic area. Results show that the cholinergic lesions effectively removed cholinergic inputs to the hippocampus, but had no significant effect on ARO or on relative levels of ER mRNAs. Likewise, injections of the cholinesterase inhibitors had no effect on ARO or ER expression in most regions of the brain. This suggests that effects of cholinergic inputs on synaptic plasticity and neuronal function are not mediated by effects on local estrogen production or ER expression. One exception was the amygdala where treating with galantamine was associated with a significant increase in ARO activity. The amygdala is a key structure involved in registering fear and anxiety. Hence this finding may be clinically relevant to elderly patients who are treated for memory impairment and who also struggle with fear and anxiety disorders.